Karyopharm(KPTI)

1.13 -0.08 -6.61%

今开:1.22昨收:1.21
最高:1.245 最低:1.08
涨停价:0.0跌停价:0.0
总市值:1.2942341E8

Karyopharm的热门讨论

chuminhua2020-12-19 23:29

12.18,Karyopharm Therapeutics周五表示,FDA批准了Xpovio (selinexor)与硼替佐米和地塞米松联合使用,用于既往至少接受过一次治疗的多发性骨髓瘤成,年患者。这种核输出抑制剂去年获得加速批准,与地塞米松联合使用,用于某些接受过四种或更多先前疗法的复发或难治性多发性骨髓瘤成人。该公司表示...查看全文

德琪ATG-010 (XPOVIO)由FDA提前三个月批准二线骨髓瘤方案,并已提交新加坡和...

E药经理人2020-12-21 22:00

--口服XPOVIO®作为联用疗法,获批用于既往接受过至少一线治疗的多发性骨髓瘤患者,显著扩展了XPOVIO®可治疗的患者群体–
--口服XPOVIO®是目前唯一一种获批联合硼替佐米(每周一次)使用的多发性骨髓瘤药物–
--自2016年起,首款获FDA批准的全新作用机...查看全文

Karyopharm(KPTI)2022-02-10 07:33

$Karyopharm(KPTI)$ 内部交易: 2022-02-07,Director,Kauffman Michael ,卖出,6764普通股, $9.86查看全文

持股变动声明

Karyopharm(KPTI)2022-02-10 06:27

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-008119  Size: 7 KB 网页链接查看全文

持股变动声明

Karyopharm(KPTI)2022-02-10 06:33

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-008124  Size: 7 KB 网页链接查看全文

持股变动声明

Karyopharm(KPTI)2022-02-10 06:33

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-008126  Size: 5 KB 网页链接查看全文

当期报告

Karyopharm(KPTI)2022-02-08 21:21

$Karyopharm(KPTI)$ 8-K Current report, items 2.02, 8.01, and 9.01 Accession Number: 0001193125-22-030469  Act: 34  Size: 345 KB 网页链接查看全文

Karyopharm(KPTI)2022-02-10 07:33

$Karyopharm(KPTI)$ 内部交易: 2022-02-07,Chief Scientific Officer,Shacham Sharon ,卖出,6764普通股, $9.86查看全文

Karyopharm(KPTI)2022-02-10 07:33

$Karyopharm(KPTI)$ 内部交易: 2022-02-07,Director,Kauffman Michael ,卖出,6707普通股, $9.86查看全文

持股变动声明

Karyopharm(KPTI)2022-02-10 06:33

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-008128  Size: 5 KB 网页链接查看全文

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73

Karyopharm的最新讨论

LAES16802-06 01:29

$Karyopharm(KPTI)$ 逆市飘扬,传被一家大型公司收购。查看全文

LAES16802-01 08:54

$Karyopharm(KPTI)$ 尾盘1️⃣笔50多万砸给了自己人,盘后又收回。看来要启动了查看全文

转出首个上市产品的部分商业化权利,德琪医药意欲何为?

药智网2023-08-24 15:20

来源:药智网公众号
图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文

不入流资讯2023-07-18 17:23

$Karyopharm(KPTI)$ Karyopharm Theraoeutics climbs 25% after securing FDA fast track designation for Selinexor for treatment of Myelofibrosis #AI_Mover#查看全文

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Karyopharm的公告

持股变动声明

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-017237  Size: 6 KB 网页链接

当期报告

$Karyopharm(KPTI)$ 8-K Current report, item 8.01 Accession Number: 0001193125-24-039387  Act: 34  Size: 144 KB 网页链接

超过5%股东持股披露「修订」

$Karyopharm(KPTI)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001306923-24-000004  Act: 34  Size: 12 KB 网页链接

超过5%股东持股披露「修订」

$Karyopharm(KPTI)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-001291  Act: 34  Size: 218 KB 网页链接

超过5%股东持股披露

$Karyopharm(KPTI)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-021272  Act: 34  Size: 13 KB 网页链接

超过5%股东持股披露「修订」

$Karyopharm(KPTI)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-013556  Act: 34  Size: 77 KB 网页链接

持股变动声明

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-012832  Size: 4 KB 网页链接

持股变动声明

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-012824  Size: 4 KB 网页链接

持股变动声明

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007621  Size: 5 KB 网页链接

持股变动声明

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-007614  Size: 5 KB 网页链接

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95